Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1

Conditions

Breast Neoplasms 2Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Lung Neoplasms 1Kidney Neoplasms 1

Interventions

Cisplatin 72Brachytherapy 31Radiotherapy 26Paclitaxel 23Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 21human papillomavirus vaccine, L1 type 16, 18 20Topotecan 18Papillomavirus Vaccines 18Carboplatin 18Surveys and Questionnaires 17Bevacizumab 16pembrolizumab 14Radiation 12Gemcitabine 12Early Intervention, Educational 12Colposcopy 12Methods 11Magnetic Resonance Spectroscopy 11atezolizumab 10Radiotherapy, Intensity-Modulated 10Blood Specimen Collection 10Papanicolaou Test 9Docetaxel 9Vaccines, Synthetic 8Platinum 8Nivolumab 8Ipilimumab 8Counseling 81,2-diaminocyclohexaneplatinum II citrate 8Vaccines 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Uterine Cervical Neoplasms × Technetium Tc 99m Sestamibi × Clear all
NCT00069160 2012-10-12

Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
48 enrolled 13 charts
GenitourinaryGynecologicThoracic

Uterine Cervical Neoplasms, Kidney Neoplasms, Lung Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡